Provided by Tiger Trade Technology Pte. Ltd.

XTL Biopharmaceuticals

2.71
-0.0700-2.52%
Volume:823
Turnover:2.24K
Market Cap:6.66M
PE:-0.87
High:2.71
Open:2.71
Low:2.71
Close:2.78
52wk High:10.28
52wk Low:2.01
Shares:2.46M
Float Shares:1.38M
Volume Ratio:0.06
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1316
EPS(LYR):-5.9716
ROE:-29.30%
ROA:-21.01%
PB:-26.22
PE(LYR):-0.45

Loading ...

XTL Biopharmaceuticals Faces Derivative Action Bid Over Failed Social Proxy Acquisition

TIPRANKS
·
Aug 06

XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period

TIPRANKS
·
Jul 22

XTL Biopharmaceuticals Completes Psyga Bio Acquisition, Refocuses on Psychedelic Medicine

TIPRANKS
·
Jul 01

XTL Biopharmaceuticals Shareholders Approve Psyga Bio Acquisition and Major Capital Increase

TIPRANKS
·
Jun 30

XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026

TIPRANKS
·
Jun 23

XTL Biopharmaceuticals Gets Nasdaq Noncompliance Notice

MT Newswires Live
·
May 23

XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report

TIPRANKS
·
May 23

XTL Announces Receipt of Staff Delist Determination from Nasdaq

GlobeNewswire
·
May 23

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

TIPRANKS
·
May 16

XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal

TIPRANKS
·
May 07

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline

TIPRANKS
·
Apr 29

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

GlobeNewswire
·
Apr 29

XTL Biopharmaceuticals trading halted, news pending

TIPRANKS
·
Mar 25

XTL Biopharmaceuticals to Change ADS Ratio

MT Newswires Live
·
Mar 21

XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026

TIPRANKS
·
Mar 21

Beyond Air announces termination of NeuroNOS agreement with XTL

TIPRANKS
·
Mar 10

XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination

TIPRANKS
·
Feb 28

XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing

TIPRANKS
·
Feb 28

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

GlobeNewswire
·
Feb 28